Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences -- Ignore unavailable to you. Want to Upgrade?

To: mokelumne river who wrote (2008)	7/29/2016 11:51:27 AM
From: eico20	Read Replies (1) \| Respond to of 2026

APRI ain’t dead yet, they have one hand left to play, that is Vitaros. Bad partner deals with large pharma – aka. Abbott, Sandoz and Takeda - really screwed sales and launches, here’s a list of actions and catalysts Apricus is executing on to get the value out of Vitaros. With nothing left in the near term, once these action items are completed, it seems to me they would probably sell the company. Vitaros is a viable, royalty producing, niche product, that once available worldwide in room temp version, can produce good income. Upcoming Vitaros catalysts to create meaningful sales: 1. A new cold temp dispensing device with longer out of fridge shelf life (7 days), should be available soon. The new cold chain dispenser has better materials, a softer tip, will last a week out of the fridge and have a better glide mechanism, easier to dispense, patient education is the key to success with the product, in other words shoot it down the hole. 2. Ferring, a smaller more committed to Vitaros company like Majorelle, has taken over the Takeda and Sandoz partnerships in all their territories, and start will selling again, the Germany launch is important. 3. Approval in Mexico then Brazil for Ferring, using UK approval portfolio 4. Mylan comes back on board with a plan for Vitaros, in discussions again due to increase in shelf life. 5. NDA in USA submittal in Q3 16, Approval in USA mid 2017, this is the biggest catalyst 6. More Recordati launches in EU – 2016 - Up to ten additional Vitaros launches in EU, Latin America and Middle East 2016- mid 2017 7. Launches in 3 countries in Mid East, using UK approval portfolio, Lebanon approved 8. Cash flow positive by end of 2017 - Targeting profitability in 2017 9. Rayva Ex-USA deal w/ current partner in EU, possible 2H 2016, for much needed cash 10. Maybe they add another DDAIP product 11. Partner deal in China/Japan